Evidence map›Paper›PMID 38944797›Full record

ArticleCytotherapy2024

Environmental monitoring of current good manufacturing practices cleanroom facilities for manufacturing of cellular therapy products in an academic hospital setting.

Jay Tanna, Chase D McCann, Rhonda Smith, Adriana Pitino, Almaz Asgedom, Srey Leap Kong, You Lian Weiner, Kathryn Bushnell, Jennifer Webb, Patrick J Hanley

Abstract read
In one paragraph

Article in Cytotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jay TannaCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Chase D McCannCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA; Department of Pediatrics, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA.
Rhonda SmithCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Adriana PitinoCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Almaz AsgedomCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Srey Leap KongCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
You Lian WeinerCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Kathryn BushnellCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Jennifer WebbCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA; Department of Pediatrics, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA.
Patrick J HanleyCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA; Department of Pediatrics, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA. Electronic address: phanley@childrensnational.org.

Funding

PR1-specific CB T cells for Patients with Myeloid MalignanciesP01CA148600 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KAUR, INDRESHPAL · 2011 to 2022
$24.4M
Targeting MRDP01CA225618 · NCI · JOHNS HOPKINS UNIVERSITY · PI Catherine M. Bollard, KENNETH R COOKE · 2019 to 2026
$15.1M
NextGen - CRIOT2CA278700 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI Catherine M. Bollard · 2022 to 2026
$5.6M
NCI NIH HHS OT2 CA278700NCI NIH HHS P01 CA148600NCI NIH HHS P01 CA225618
6 · The paper itself

Abstract

As the field of cell and gene therapy (CGT) continues to grow, so too must the infrastructure and regulatory guidance supporting the manufacture of these potentially life-saving products-especially early-phase products manufactured at an increasing number of academic or hospital-based facilities providing decentralized (or point of care) manufacturing. An important component of current good manufacturing practices, including those regulating cell and gene therapies, is the establishment of an effective environmental monitoring (EM) program. While several guidelines for establishing an EM program are available, these guidelines do not specifically address the unique aspects of manufacturing CGT products and they do not provide real-world evidence demonstrating the effectiveness of the program. Here, we describe the establishment and evolution of an EM program in a cell therapy manufacturing facility at an academic hospital. With 10 years of EM data, we analyze the effectiveness for identifying trends in environmental conditions and highlight important findings, with the aim of providing practical evidence and guidance for the development of future early-phase EM programs.

Indexed as

Cell- and Tissue-Based TherapyEnvironmental MonitoringAcademic Medical CentersEnvironment, ControlledHumanscell therapycleanroomenvironmental monitoringGMPmanufacturing

Identifiers

PMID38944797
PMCPMC11471380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.